Glaukos Corporation (GKOS)
GKOS Stock Price Chart
Explore Glaukos Corporation interactive price chart. Choose custom timeframes to analyze GKOS price movements and trends.
GKOS Company Profile
Discover essential business fundamentals and corporate details for Glaukos Corporation (GKOS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
25 Jun 2015
Employees
995.00
Website
https://www.glaukos.comCEO
Thomas William Burns
Description
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
GKOS Financial Timeline
Browse a chronological timeline of Glaukos Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.22, while revenue estimate is $150.99m.
Earnings released on 29 Apr 2026
EPS came in at -$0.18 surpassing the estimated -$0.30 by +40.00%, while revenue for the quarter reached $150.57m , beating expectations by +9.91%.
Earnings released on 17 Feb 2026
EPS came in at -$0.28 falling short of the estimated -$0.22 by -27.27%, while revenue for the quarter reached $143.12m , beating expectations by +4.93%.
Earnings released on 29 Oct 2025
EPS came in at -$0.16 surpassing the estimated -$0.27 by +40.74%, while revenue for the quarter reached $133.54m , beating expectations by +3.15%.
Earnings released on 30 Jul 2025
EPS came in at -$0.24 surpassing the estimated -$0.26 by +7.69%, while revenue for the quarter reached $124.12m , beating expectations by +1.38%.
Earnings released on 30 Apr 2025
EPS came in at -$0.22 surpassing the estimated -$0.33 by +33.33%, while revenue for the quarter reached $106.66m , beating expectations by +3.78%.
Earnings released on 20 Feb 2025
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.26%, while revenue for the quarter reached $105.50m , beating expectations by +4.50%.
Earnings released on 4 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.52 by +46.15%, while revenue for the quarter reached $96.67m , missing expectations by -3.84%.
Earnings released on 31 Jul 2024
EPS came in at -$0.52 matching the estimated -$0.52, while revenue for the quarter reached $95.69m , beating expectations by +7.65%.
Earnings released on 1 May 2024
EPS came in at -$0.70 falling short of the estimated -$0.58 by -20.69%, while revenue for the quarter reached $85.62m , beating expectations by +7.57%.
Earnings released on 21 Feb 2024
EPS came in at -$0.63 falling short of the estimated -$0.56 by -12.50%, while revenue for the quarter reached $82.37m , beating expectations by +5.56%.
Earnings released on 1 Nov 2023
EPS came in at -$0.50 surpassing the estimated -$0.56 by +10.71%, while revenue for the quarter reached $78.05m , beating expectations by +3.72%.
Earnings released on 2 Aug 2023
EPS came in at -$0.55 surpassing the estimated -$0.57 by +3.51%, while revenue for the quarter reached $80.40m , beating expectations by +7.59%.
Earnings released on 3 May 2023
EPS came in at -$0.59 surpassing the estimated -$0.61 by +3.28%, while revenue for the quarter reached $73.90m , beating expectations by +9.12%.
Earnings released on 22 Feb 2023
EPS came in at -$0.53 surpassing the estimated -$0.56 by +5.36%, while revenue for the quarter reached $71.23m , beating expectations by +4.63%.
Earnings released on 2 Nov 2022
EPS came in at -$0.45 surpassing the estimated -$0.53 by +15.09%, while revenue for the quarter reached $71.27m , beating expectations by +4.87%.
Earnings released on 3 Aug 2022
EPS came in at -$0.83 falling short of the estimated -$0.44 by -88.64%, while revenue for the quarter reached $72.69m , beating expectations by +6.91%.
Earnings released on 4 May 2022
EPS came in at -$0.38 surpassing the estimated -$0.52 by +26.92%, while revenue for the quarter reached $67.68m , beating expectations by +11.22%.
Earnings released on 22 Feb 2022
EPS came in at -$0.31 surpassing the estimated -$0.37 by +16.22%, while revenue for the quarter reached $73.24m , beating expectations by +8.86%.
Earnings released on 4 Nov 2021
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $74.71m , beating expectations by +2.33%.
Earnings released on 5 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.24 by +54.17%, while revenue for the quarter reached $78.09m , meeting expectations.
GKOS Stock Performance
Access detailed GKOS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
